"Scientists Identify Novel Therapeutic Targets For Metastatic Melanoma"
Mount Sinai researchers have identified novel therapeutic targets for metastatic melanoma, according to a study published in Molecular Cell. "Melanoma is the most aggressive form of skin cancer, affecting more and more patients," according to the study's senior author, Emily Bernstein, PhD, associate professor of oncological sciences and dermatology at the Icahn School of Medicine at Mount Sinai. "While immunotherapy and targeted therapies have significantly improved the outcome for some metastatic melanoma patients, they have had success in a small subset of patients and can cause significant toxic side effects. Thus, their limitations underscore the need for new therapies, highlighting the importance of this research's discovery of novel targets." The researchers made their discoveries by studying BET proteins, which regulate gene expression in cancer, and their regulation of AMIGO2. When melanoma is growing, the amount of AMIGO2 increases; silencing its function significantly impairs melanoma's growth.
- Emily Bernstein, PhD, Associate Professor, Oncological Sciences, Dermatology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Additional coverage: